ReviewThe Journal of clinical investigation2014
The genetics and immunobiology of IgA nephropathy.
Review in The Journal of clinical investigation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
132 citing papers in PubMed, 2 syntheses or guidelines pooled it, 215 citations in OpenAlex.
- Risk factors for recurrent IgA nephropathy after renal transplantation: A meta-analysis.Biomolecules & biomedicine · 2023Pooled it
- Pooled it
- A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.The New England journal of medicine · 2024Trial
- A Rare Genetic Defect ofFrontiers in immunology · 2019Trial
- Targeting the B-Cell Activating Factor and a Proliferation-Inducing Ligand Pathway in IgAN: From Disease Pathogenesis to Clinical Trial Evidence.Kidney international reports · 2026Review
- The expanding role of biomarkers in the management of IgA nephropathy.Kidney international supplements · 2026Review
- IgA nephropathy: an overview of the disease, its pathophysiology, and involvement of the gut-kidney axis.Kidney international supplements · 2026Review
- Management of IgA nephropathy and the expanding role of immunomodulation.Kidney international supplements · 2026Review
- NR1H4 downregulation facilitates abnormal cell proliferation contributing to IgA nephropathy pathogenesis, with potential clinical implications.Human cell · 2026Article
- Ophiocordyceps indica from the Indian Himalayas Ameliorates the IgA Nephropathy in Mice.Applied biochemistry and biotechnology · 2026Article
- ACSL4 mediates ferroptosis to promote immunoglobulin A nephropathy progression: scRNA-seq analysis.Scientific reports · 2026Article
- Aberrant signaling in tonsillar B cells producing pathogenicFrontiers in immunology · 2026Review
- Real-world study of telitacicept in the treatment of IgA nephropathy.Frontiers in immunology · 2026Article
- Tfh Cells in Henoch-Schönlein Purpura (IgA Vasculitis): Current Concept.Journal of immunology research · 2026Review
- The role of mucosal immune dysregulation in the pathogenesis of immunoglobulin A nephropathy.Frontiers in immunology · 2026Review
- The Impact of Complement Factor H-Related Protein Gene Deletions on Kidney Transplantation.Scandinavian journal of immunology · 2025Article
- Immunoglobulin A Nephropathy in a Kidney Transplant Recipient with Kabuki Syndrome.Internal medicine (Tokyo, Japan) · 2025Article
- Integrative bioinformatics analysis unveils hub transcription factors and their interacting drugs in immunoglobulin A nephropathy: Implications for pathogenesis and treatments.Journal, genetic engineering & biotechnology · 2025Article
- Exploring the mediating role of immune cells in the pathogenesis of IgA nephropathy through the inflammatory axis of gut microbiota from a genomic perspective.Mammalian genome : official journal of the International Mammalian Genome Society · 2025Article
- Single-Cell RNA-Sequencing Analysis Provides Insights into IgA Nephropathy.Biomolecules · 2025Review
72 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
IgA nephropathy (IgAN) represents the leading cause of kidney failure among East Asian populations and the most frequent form of primary glomerulonephritis among Europeans. Patients with IgAN develop characteristic IgA1-containing immune complexes that deposit in the glomerular mesangium, producing progressive kidney injury. Recent studies define IgAN as an autoimmune trait of complex architecture with a strong genetic determination. This Review summarizes new insights into the role of the O-glycosylation pathway, anti-glycan immune response, mucosal immunity, antigen processing and presentation, and the alternative complement pathway in the pathogenesis of IgAN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.